Hi James, Just a quick question regarding Cantrixil. I read that Final Data from P1 study was due at ESMO 19-21 September 2020 (Hidden Gems Webinar). Also I noticed that Cantrixil was left out of P16 on the HC Wainwright presentation. Any possible update on this would be appreciated. Thank you for all the work you & the team have been doing & I like many others look forward to the data read outs over the next 6-12 months regarding both Paxalisib & Cantrixil. Regards, MrDB
Dear MrDB, After discussion with the investigators, we decided not to put Cantrixil into the ESMO conference. Like many conferences, this has moved to a wholly virtual format, and we took the view that it would not provide good exposure for the final data from the study. We are working to find a better forum to present the definitive results. Meanwhile, as reflected in our more recent guidance, we expect to share at least top-level data in the second half. All best wishes, James.
”we expect to share at least top-level data in the second half”
the company has always indicated that they would do a deal / partnership regarding Cantrixil
- Forums
- ASX - By Stock
- KZA
- Cantrixil
Cantrixil
-
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online